On April 25, 2024, OncoCyte Corporation closed the transaction. The transaction included participation from 21 investors pursuant to Regulation D.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.955 USD | -3.75% | +2.25% | +18.20% |
May. 15 | Transcript : OncoCyte Corporation, Q1 2024 Earnings Call, May 15, 2024 | |
May. 15 | Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q1 Revenue $176,000, vs. Street Est of $0.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.20% | 41.03M | |
+9.47% | 114B | |
+11.57% | 104B | |
-13.79% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.57% | 17.89B | |
+7.48% | 14.28B | |
+35.67% | 12.55B |
- Stock Market
- Equities
- OCX Stock
- News OncoCyte Corporation
- OncoCyte Corporation announced that it has received $15.807655 million in funding